Table 1. Clinicopathological characteristics of the Norwegian and Australian SOC patients.
| Norwegian cohort | Australian cohort | ||||||||
| All | TAI<med.1 | TAI>med.1 | p* | All | TAI<med.1 | TAI>med.1 | p* | ||
| Patients | Total cases | 74 (100%) | 37 (50%) | 37 (50%) | 70 (100%) | 35 (50%) | 35 (50%) | ||
| Age | Mean (SD) | 60 (11) | 60 (11) | 60 (10) | 57 (11) | 55 (12) | 58 (9) | ||
| Range | 38–81 | 39–79 | 38–81 | 23–80 | 23–78 | 44–80 | |||
| Age groups | <45 | 7 (10%) | 4 (11%) | 3 (8%) | 0.711 | 6 (9%) | 5 (14%) | 1 (3%) | 0.226 |
| 45–55 | 15 (20%) | 6 (16%) | 9 (24%) | 25 (36%) | 12 (34%) | 13 (37%) | |||
| >55 | 52 (70%) | 27 (73%) | 25 (68%) | 39 (56%) | 18 (51%) | 21 (60%) | |||
| Stage | II | 3 (4%) | 1 (3%) | 2 (5%) | 0.958 | 0 (0%) | 0 (0%) | 0 (0%) | 0.462 |
| III (B+C) | 50 (68%) | 26 (70%) | 24 (65%) | 62 (89%) | 30 (86%) | 32 (91%) | |||
| IV | 21 (28%) | 10 (27%) | 11 (30%) | 8 (11%) | 5 (14%) | 3 (9%) | |||
| Grade | 1 | 3 (4%) | 2 (5%) | 1 (3%) | 0.186 | 4 (6%) | 2 (6%) | 2 (6%) | 0.656 |
| 2 | 21 (28%) | 7(19%) | 14 (38%) | 24 (34%) | 10 (29%) | 14 (40%) | |||
| 3 | 50 (68%) | 28(76%) | 22 (60%) | 40 (57%) | 22 (63%) | 18 (51%) | |||
| Chemotherapy | Sensitive | 51 (69%) | 21 (57%) | 30 (81%) | 0.043 | 39 (56%) | 17 (49%) | 22 (63%) | 0.336 |
| Resistant | 23 (31%) | 16 (43%) | 7 (19%) | 31 (44%) | 18 (51%) | 13 (37%) | |||
| Progression | Progression | 69 (93%) | 36 (97%) | 33 (89%) | 0.358 | 63 (90%) | 3 (9%) | 4 (11%) | 1 |
| No progression | 5 (7%) | 1 (3%) | 4 (11%) | 7 (10%) | 32 (91%) | 31 (87%) | |||
| PFS (months) | Median | 16 | 15 | 18 | 15 | 12 | 19 | ||
| (95% CI) | 14–21 | 10–18 | 15–26 | 11–20 | 10–19 | 13–23 | |||
| OS (months) | Median | 32 | 25 | 50 | 40 | 25 | 47 | ||
| (95% CI) | 25–47 | 17–31 | 34–67 | 28–54 | 19–57 | 35–60 | |||
1Genomic instability was quantified as below (TAI<med.) or above (TAI>med.) median TAI. The median was 0.135 for the Norwegian cohort and 0.242 for the Australian cohort.
*
Calculated p-values for age, stage, and grade from Mann-Whitney tests and for chemotherapy and progression from Fisher's exact tests.
Abbreviations: SOC, serous ovarian cancers; TAI, Total Aberration Index; PFS, progression-free survival; OS, overall survival; CI, confidence interval.